Interleukin-1 receptor antagonist for refractory anti-MDA5 clinically amyopathic dermatomyopathy
1. 系统已在2025-11-13 14:53:08对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接: https://pubmed.ncbi.nlm.nih.gov/26343354
其他信息:
PMID: 26343354
作者: M Groh; K Rogowska; O Monsarrat; A Denoël; P Blanche; ...
摘要: Autoantibodies targeting the melanoma-differentiation-associated gene-5 (MDA5)-encoded ribonucleic acid helicase are associated with clinically amyopathic dermatomyopathy (CADM). Marked systemic inflammation, skin ulcers and severe interstitial lung disease seem frequent. DM treatment consists of immunosuppressants and/or intravenous immunoglobulins, but evidence-based knowledge is lacking. Anakinra (an interleukin-1 receptor antagonist (IL-1RA)) use in this setting has never been reported. Here...
